The US labels for Ozempic, Wegovy, Mounjaro and Zepbound do not say anything about drinking alcohol. They list no alcohol interaction and give no drinking limit. Separately, researchers are testing whether GLP-1 drugs reduce drinking in people with alcohol use disorder. One small semaglutide trial found less drinking and less craving. An earlier exenatide trial missed its main goal. None of these drugs is approved to treat alcohol use disorder. This guide covers what the labels actually say, what the trials found, and where the evidence stops.
Alcohol use disorder, or AUD, is the medical term for a pattern of drinking that a person has trouble controlling and that causes harm. You will see the abbreviation below.
We downloaded the current US prescribing information for all four brands and searched each one for "alcohol" and "ethanol." Here is every kind of hit.
| Label (revision) | Where "alcohol" appears | Anything about drinking? |
|---|---|---|
| Ozempic (05/2026) | Alcohol swab or wipe in the instructions for use | No |
| Wegovy (06/2026) | Alcohol swab or wipe; the liver disease names "nonalcoholic steatohepatitis" and "non-alcoholic fatty liver disease" | No |
| Mounjaro (08/2026) | Benzyl alcohol, an inactive ingredient in the multi-dose vial and KwikPen (11) | No |
| Zepbound (08/2026) | Benzyl alcohol, an inactive ingredient in the multi-dose vial and KwikPen (11) | No |
That is the full list. The alcohol swab is for cleaning the skin before an injection. Benzyl alcohol is listed as one of the excipients, the inactive ingredients, in the Mounjaro and Zepbound multi-dose vial and KwikPen, at 5.4 mg per dose (Mounjaro label, 11; Zepbound label, 11). The Wegovy hits are liver disease names: the label says MASH, a liver condition Wegovy is approved to treat, was "formerly known as nonalcoholic steatohepatitis." None of these is about drinking.
The labels also list no alcohol use disorder indication. In other words, the FDA has not approved any of these four drugs to treat drinking problems. Anything you read about GLP-1s for alcohol is based on research, not on approved use.
The labels do not connect any warning to alcohol. Still, three of their warnings involve symptoms or situations that are worth raising with your prescriber if you drink.
| Warning | Ozempic | Wegovy | Mounjaro | Zepbound |
|---|---|---|---|---|
| Acute pancreatitis | 5.2 | 5.2 | 5.2 | 5.5 |
| Low blood sugar | 5.5 | 5.4 | 5.3 | 5.7 |
| Kidney injury from dehydration | 5.6 | 5.5 | 5.5 | 5.3 |
Again, these are label warnings, not alcohol warnings. Whether and how much you drink is a question for your prescriber, who knows your other medicines and your health history.
Animal studies are part of the reason. The exenatide trial authors note that exenatide reduces alcohol drinking in rodents and in nonhuman primates. The semaglutide trial authors write that "preclinical, observational, and pharmacoepidemiology evidence" suggests GLP-1 drugs may reduce alcohol intake, and that randomized trials were needed to see whether that holds up in people. A randomized trial is one where a coin-flip process decides who gets the drug and who gets placebo, a look-alike with no drug in it. It is the best way to tell whether a drug caused a change.
This was a phase 2 trial, meaning an early, smaller test of whether a drug works, run at one US academic medical center. It enrolled 48 adults with AUD who were not seeking treatment. 71% were women and the average age was 39.9 years. They got weekly semaglutide or placebo for 9 weeks (Hendershot et al., 2025).
The authors call this low-dose semaglutide: 0.25 mg a week for 4 weeks, 0.5 mg a week for 4 weeks, then 1.0 mg for 1 week. The main test happened at the 0.5 mg dose. People came into a lab and were offered alcohol, and researchers measured how much they chose to drink.
What the paper reports:
The authors call this "initial prospective evidence" and say it justifies larger trials. That is the right way to read it. It is one small, short study in people who were not trying to quit, and it found changes in some drinking measures but not others.
Exenatide is another GLP-1 drug. This trial gave 127 adults with AUD who were seeking treatment either exenatide 2 mg once a week or placebo for 26 weeks. Everyone also got cognitive behavioral therapy, a standard talk therapy for AUD (Klausen et al., 2022).
Exploratory subgroup results like these are ideas for future studies, not findings to act on. The groups are small, and the opposite results in leaner and heavier people show how unsettled this is. Side effects were mainly stomach and gut related.
A Swedish study looked at national health records from 2006 to 2023 for 227,866 people aged 16 to 64 with an AUD diagnosis (Lähteenvuo et al., 2025). It compared each person's time on a GLP-1 drug with their own time off it. During semaglutide use (4,321 users), the risk of being hospitalized for AUD was lower, with an adjusted hazard ratio of 0.64. A hazard ratio below 1 means a lower rate; 0.64 is roughly a third lower. Liraglutide use (2,509 users) had a hazard ratio of 0.72. Use of medicines approved for AUD had a hazard ratio of 0.98.
This is an association. It cannot prove the drug caused the drop. People who start a GLP-1 may differ in other ways during that time of their lives. The authors themselves say clinical trials "are urgently needed to confirm these findings."
| Study | Who | Length | Main result |
|---|---|---|---|
| Hendershot 2025 (semaglutide, RCT) | 48 adults with AUD, not seeking treatment | 9 weeks | Less alcohol drunk in a lab test; fewer drinks per drinking day; less craving |
| Klausen 2022 (exenatide, RCT) | 127 adults with AUD, seeking treatment | 26 weeks | No difference in heavy drinking days (main outcome) |
| Lähteenvuo 2025 (Swedish registry) | 227,866 people with AUD | Median 8.8 years of follow-up | Semaglutide use linked to lower risk of AUD hospital stays (aHR 0.64) |
If your drinking worries you, that is worth raising directly with a doctor. There are treatments made for it, and a GLP-1 prescribed for weight or diabetes is not a substitute for that care.
Since the labels are silent, there is no official rule to quote. The practical steps are simple:
Dose Track can make that record easy. It logs every dose across your compounds, sends reminders, tracks vials and supplies, and lets you log side effects with notes, so you can show your prescriber what happened and when. For stomach side effects in general, see GLP-1 nausea: what the labels say. If weight loss has stalled, see the GLP-1 weight-loss plateau guide. You can also compare the drugs in semaglutide vs tirzepatide.
This article is general information, not medical advice. Talk to your prescriber before you start, change or stop any medicine.